Neuroendocrine tumours (NETs) represent a rare and highly heterogeneous entity, with increasing incidence [1], [2]. More than 50% of NETs arise from the gastrointestinal tract and pancreas [3]. About half are metastatic at presentation [4].

Treatment options approved for patients with advanced gastro-enteropancreatic NETs (GEP-NETs) include long-acting somatostatin analogues (SSAs), targeted therapy (TT), chemotherapy (CT) and peptide receptor radionuclide therapy (PRRT) as the main options. The question of the optimal sequence of therapies remains open.

Where appropriate, levels of evidence and grades of recommendation have been applied using the system adapted from the Infectious Diseases Society of America-United States Public Health Service Grading System [5], [6].